ozagrel and Carcinoma--Hepatocellular

ozagrel has been researched along with Carcinoma--Hepatocellular* in 1 studies

1 trial(s) available for ozagrel and Carcinoma--Hepatocellular

Article	Year
A thromboxane A2 synthetase inhibitor, OKY-046, reduces liver damage in hepatectomy. Surgery, 1993, Volume: 114, Issue:5 Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Diseases; Liver Neoplasms; Methacrylates; Thromboxane-A Synthase	1993